These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36494685)

  • 1. Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis.
    Choi MG; Choi SM; Lee JH; Kim JY; Song JW
    Respir Res; 2022 Dec; 23(1):334. PubMed ID: 36494685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline serum Krebs von den Lungen-6 as a biomarker for the disease progression in idiopathic pulmonary fibrosis.
    Chung C; Kim J; Cho HS; Kim HC
    Sci Rep; 2022 May; 12(1):8564. PubMed ID: 35595812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease.
    Ko UW; Cho EJ; Oh HB; Koo HJ; Do KH; Song JW
    PLoS One; 2020; 15(12):e0244114. PubMed ID: 33332430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study.
    Huang TH; Kuo CW; Chen CW; Tseng YL; Wu CL; Lin SH
    BMC Pulm Med; 2021 May; 21(1):165. PubMed ID: 33992083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.
    Xue M; Guo Z; Cai C; Sun B; Wang H
    Respiration; 2019; 98(6):534-545. PubMed ID: 31665737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia.
    Yamakawa H; Hagiwara E; Ikeda S; Iwasawa T; Otoshi R; Tabata E; Okuda R; Sekine A; Baba T; Iso S; Okudela K; Takemura T; Ogura T
    Respir Investig; 2019 Sep; 57(5):422-429. PubMed ID: 31003951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].
    Sun D; Cheng Z; Jiang TC; Li PF; Jia LQ; Wang TT; Zheng CP; Li Y; Duo MJ
    Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(10):748-752. PubMed ID: 32192286
    [No Abstract]   [Full Text] [Related]  

  • 10. Circulatory Serum Krebs von Den Lungen-6 and Surfactant Protein-D Concentrations Predict Interstitial Lung Disease Progression and Mortality.
    Rai M; Parthasarathi A; Beeraka NM; Kaleem Ullah M; Malamardi S; Padukudru S; Siddaiah JB; Uthaiah CA; Vishwanath P; Chaya SK; Ramaswamy S; Upadhyay S; Ganguly K; Mahesh PA
    Cells; 2023 Apr; 12(9):. PubMed ID: 37174681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic performance of Krebs von den Lungen-6, surfactant protein A, surfactant protein D levels in the serum and bronchoalveolar lavage fluid in chronic fibrosing interstitial pneumonia: a retrospective study.
    Wakamatsu K; Nagata N; Kumazoe H; Hara M; Asai S; Noda N; Kiyotani R; Fukui I; Tatsuta M; Katahira K; Akasaki T; Maki S; Miyamoto K; Otsuka J; Izumi M; Kawasaki M; Yamada H
    BMC Pulm Med; 2024 Aug; 24(1):404. PubMed ID: 39174992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of Krebs von den Lungen-6 (KL-6) measurement in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
    Aloisio E; Braga F; Puricelli C; Panteghini M
    Clin Chem Lab Med; 2021 Jul; 59(8):1400-1408. PubMed ID: 33831978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Krebs von den Lungen-6 as a Potential Predictive Biomarker in Fibrosing Interstitial Lung Diseases.
    Lederer C; Mayer K; Somogyi V; Kriegsmann K; Kriegsmann M; Buschulte K; Polke M; Findeisen P; Herth F; Kreuter M
    Respiration; 2023; 102(8):591-600. PubMed ID: 37586349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial Measurements of Circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and Periostin in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Therapy: An Exploratory Study.
    Majewski S; Szewczyk K; Żal A; Białas AJ; Miłkowska-Dymanowska J; Piotrowski WJ
    J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Research on Prognostic Evaluation of Subjects With IPF by Peripheral Blood Biomarkers, Quantitative Imaging Characteristics and Pulmonary Function Parameters.
    Guo L; Yang Y; Liu F; Jiang C; Yang Y; Pu H; Li W; Zhong Z
    Arch Bronconeumol (Engl Ed); 2020 Jun; 56(6):365-372. PubMed ID: 31740085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy.
    d'Alessandro M; Bergantini L; Cameli P; Pieroni M; Refini RM; Sestini P; Bargagli E
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33572070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis.
    Okamoto T; Fujii M; Furusawa H; Tsuchiya K; Miyazaki Y; Inase N
    Respir Med; 2015 Dec; 109(12):1576-81. PubMed ID: 26481343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study.
    Xue C; Wu N; Li X; Qiu M; Du X; Ye Q
    BMC Pulm Med; 2017 Nov; 17(1):144. PubMed ID: 29149883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
    Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
    Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.